A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
ASP3082 grabs some early attention among degraders set to feature at ESMO.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
The FDA throws out the company’s second attempt at an accelerated approval.
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.